Adenosine

Generic Name: Adenosine

Brand Names: Adenocard, Viva-drops Lubricating Eye Drops

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₃N_₅O_₄

CAS Number: 58-61-7

Unique Ingredient Identifier: K72T3FS567

Background: The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by dipyridamole and [regadenson]. Adenosine is also indicated in the treatment of supraventricular tachycardia.

Adenosine was granted FDA approval on 30 October 1989.

Indication: Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy in patients unable to adequately exercise. It is also indicated to convert sinus rhythm of paroxysmal supraventricular tachycardia.

Associated Conditions: Paroxysmal Supraventricular Tachycardia (PSVT), Pulmonary Arterial Hypertension (PAH), SVT, Supraventricular Tachycardia (SVT)

Clinical Trials

Effects of Body Mass Index on the Hyperemic Response to Regadenoson

Not Applicable

Completed

Conditions: Decreased Vascular Flow
Endothelial Dysfunction
Obesity

Interventions: Drug: Adenosine
Drug: Regadenoson

First Posted Date: 2009-03-11

Last Posted Date: 2011-05-24

Lead Sponsor: University of Utah

Target Recruit Count: 30

Registration Number: NCT00859833

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Prevention of Liver Damage During Liver Surgery

Phase 1

Conditions: Liver Tumors

Interventions: Drug: placebo
Drug: adenosine
Procedure: Liver resection

First Posted Date: 2009-02-18

Last Posted Date: 2009-02-18

Lead Sponsor: Ludwig-Maximilians - University of Munich

Registration Number: NCT00845689

Myocardial Protection With Adenosine During Primary Percutaneous Coronary Intervention in Pts With STEMI

Phase 3

Completed

Conditions: Acute Myocardial Infarction

First Posted Date: 2008-10-29

Last Posted Date: 2013-02-18

Lead Sponsor: David Garcia-Dorado

Target Recruit Count: 201

Registration Number: NCT00781404

Locations: 🇪🇸
ValldHebron Hospital, Barcelona, Spain

Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)

Phase 3

Conditions: Stable Angina
Percutaneous Coronary Intervention

Interventions: Other: placebo
Drug: Clopidogrel
Drug: Adenosin

First Posted Date: 2008-09-12

Last Posted Date: 2009-05-06

Lead Sponsor: University of Roma La Sapienza

Target Recruit Count: 60

Registration Number: NCT00751491

Locations: 🇮🇹
Policlinico Umberto I, Rome, Italy

Role of Adenosine in the Control of Choroidal Blood Flow During Changes in Ocular Perfusion Pressure.

Not Applicable

Completed

Conditions: Ocular Physiology
Microcirculation

Interventions: Drug: Placebo
Drug: Adenosine

First Posted Date: 2008-07-10

Last Posted Date: 2008-07-10

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 20

Registration Number: NCT00712764

Locations: 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

Assessment of Oxygen Changes in the Heart With Cardio-vascular Magnetic Resonance Imaging

Early Phase 1

Completed

Conditions: Vascular Diseases
Myocardial Ischemia

Interventions: Device: Breathing gas
Other: modified end-tidal forcing system
Other: arm cuff occlusion
Drug: adenosine
Device: Blood pressure cuff

First Posted Date: 2008-06-09

Last Posted Date: 2011-10-04

Lead Sponsor: University of Calgary

Target Recruit Count: 100

Registration Number: NCT00693758

Locations: 🇨🇦
Stephenson CMR Centre at Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada

Prophylactic Intra-coronary Adenosine to Prevent Post Coronary Artery Stenting Myonecrosis

Phase 3

Terminated

Conditions: Coronary Artery Stenosis
Coronary Artery Disease

Interventions: Drug: Adenosine

First Posted Date: 2008-02-11

Last Posted Date: 2012-08-29

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 200

Registration Number: NCT00612521

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction

Phase 2

Completed

Conditions: Myocardial Infarction

Interventions: Drug: placebo
Drug: nitroprusside
Drug: adenosine

First Posted Date: 2008-01-10

Last Posted Date: 2012-03-27

Lead Sponsor: Catholic University of the Sacred Heart

Target Recruit Count: 240

Registration Number: NCT00590070

Locations: 🇮🇹
Dipartimento Medicina Cardiovascolare, Rome, Italy

Role of Adenosine in the Release of VEGF and Cytokines

Phase 1

Terminated

Conditions: Inflammation

Interventions: Drug: Adenosine
Drug: Sodium Nitroprusside

First Posted Date: 2007-12-27

Last Posted Date: 2018-02-28

Lead Sponsor: Vanderbilt University

Target Recruit Count: 8

Registration Number: NCT00580905

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Clonidine Versus Adenosine to Treat Neuropathic Pain

Phase 2

Completed

Conditions: Pain

Interventions: Drug: adenosine
Drug: placebo
Drug: clonidine

First Posted Date: 2006-07-10

Last Posted Date: 2018-09-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 24

Registration Number: NCT00349921

Locations: 🇺🇸
The Center for Clinical Research, 145 Kimel Park Drive, Winston-Salem, North Carolina, United States
🇺🇸
Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy